Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.

about

Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.

Item

http://www.wikidata.org/entity/Q47135784

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Dihydropyrimidine dehydrogenas ...... gh-risk colon cancer patients.

@en

Dihydropyrimidine dehydrogenas ...... gh-risk colon cancer patients.

@nl

type

Item

label

Dihydropyrimidine dehydrogenas ...... gh-risk colon cancer patients.

@en

Dihydropyrimidine dehydrogenas ...... gh-risk colon cancer patients.

@nl

prefLabel

Dihydropyrimidine dehydrogenas ...... gh-risk colon cancer patients.

@en

Dihydropyrimidine dehydrogenas ...... gh-risk colon cancer patients.

@nl

P1476

Dihydropyrimidine dehydrogenas ...... igh-risk colon cancer patients

@en

P2093

A Bramati

http://www.w3.org/2001/XMLSchema#string

A Ruzzo

http://www.w3.org/2001/XMLSchema#string

A Sobrero

http://www.w3.org/2001/XMLSchema#string

B Massidda

http://www.w3.org/2001/XMLSchema#string

C Mucciarini

http://www.w3.org/2001/XMLSchema#string

C Verusio

http://www.w3.org/2001/XMLSchema#string

D Turci

http://www.w3.org/2001/XMLSchema#string

E Biondi

http://www.w3.org/2001/XMLSchema#string

E Rulli

http://www.w3.org/2001/XMLSchema#string

E Veltri

http://www.w3.org/2001/XMLSchema#string

P2860

Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients

Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.

Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemothera

DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).

Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing

Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients

Patterns of linkage disequilibrium in the human genome.

Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.

Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)

P2888

bjc.2017.289

P304

1269-1277

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2017.289

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-08-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29065426

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

P932

5709672

http://www.w3.org/2001/XMLSchema#string